SCHEMBL10189741

SCHEMBL10189741

COc1ccc(-c2[nH]nnc2-c2cc(C)c(C)c(OC)c2)cc1NC(C)=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.42
KMT2A Q03164 5/20 0.42
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 3/20 0.42
LMNA P02545 2/20 0.42
NPC1 O15118 1/20 0.42
TP53 P04637 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B1 P14061 1/20 0.38
HSD17B2 P37059 1/20 0.38
TSHR P16473 1/20 0.38
ADORA3 P0DMS8 3/20 0.38
DYRK1A Q13627 1/20 0.37
DYRK1B Q9Y463 1/20 0.37
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MAPT P10636 5/20 0.36
FYN P06241 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14847363 0.88 MEN1 (0.44) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL413893 0.88 ADORA3 (0.46) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL10189745 0.84 PDE4A (0.36) MEN1KMT2AALDH1A1LMNATP53
SCHEMBL10189762 0.83 MAPT (0.39) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL3304869 0.82 RXFP1 (0.40) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL10189720 0.81 TUBB1 (0.44) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL410873 0.81 KMT2A (0.41) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL10189713 0.81 MAPT (0.42) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL10189700 0.80 ALDH1A1 (0.40) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL10189712 0.79 CHEK1 (0.43) MEN1KMT2AALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9175022-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2015-11-03 US disclosed
US-8501790-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-08-06 US disclosed
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 MEN1 1571/4885KMT2A 2808/4885ALDH1A1 1872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.